FXYD6: a novel therapeutic target toward hepatocellular carcinoma
FXYD6, FXYD domain containing ion transport regulator 6, has been reported to affect the activity of Na+/K+-ATP- ase and be associated with mental diseases. Here, we demonstrate that FXYD6 is up-regulated in hepatocellular carcinoma (HCC) and enhances the migration and prolif- eration of HCC cells....
Gespeichert in:
Veröffentlicht in: | Protein & cell 2014-07, Vol.5 (7), p.532-543 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | FXYD6, FXYD domain containing ion transport regulator 6, has been reported to affect the activity of Na+/K+-ATP- ase and be associated with mental diseases. Here, we demonstrate that FXYD6 is up-regulated in hepatocellular carcinoma (HCC) and enhances the migration and prolif- eration of HCC cells. Up-regulation of FXYD6 not only positively correlates with the increase of Na+IK+-ATPase but also coordinates with the activation of its downstream Src-ERK signaling pathway. More importantly, blocking FXYD6 by its functional antibody significantly inhibits the growth potential of the xenografted HCC tumors in mice, indicating that FXYD6 represents a potential therapeutic target toward HCC. Altogether, our results establish a critical role of FXYD6 in HCC progression and suggest that the therapy targeting FXYD6 can benefit the clinical treatment toward HCC patients. |
---|---|
ISSN: | 1674-800X 1674-8018 |
DOI: | 10.1007/s13238-014-0045-0 |